PLASMAPHERESIS IN TREATMENT OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-I ASSOCIATED MYELOPATHY
PLASMAPHERESIS IN TREATMENT OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-I ASSOCIATED MYELOPATHY
复制标题
血浆去除术治疗人类 T 淋巴细胞病毒 I 型相关性骨髓病
DOI：
10.1016/s0140-6736(88)90525-9
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
S. Nagataki
中科院分区：
文献类型：
--
作者：
H. Matsuo;M. Tsujihata;A. Satoh;Susumu Shirabe;Tatsufumi Nakamura;I. Kinoshita;I. Tomita;K. Shibayama;S. Nagataki
在18例人类嗜T淋巴细胞病毒I型（HTLV-I）相关性脊髓病（HAM）患者中，11例患者的步态、感觉和/或括约肌功能障碍通过血浆置换得到改善（2周内4至6次），并且效果维持2至4周。血浆置换可降低血清中HTLV-Ⅰ抗体滴度，但对脑脊液中HTLV-Ⅰ抗体滴度无影响，且HTLV-Ⅰ抗体滴度的变化与血浆置换的效果无关。这些结果表明，血浆置换是有用的治疗，至少在产生暂时的改善，在HAM患者，和一些体液因子（S），但不是HTLV-I抗体，可能是重要的发病机制HAM。
In 11 of 18 patients with human T-lymphotropic virus type-I (HTLV-I) associated myelopathy (HAM) gait, sensory, and/or sphincter disturbance improved with plasmapheresis (4 to 6 sessions in 2 weeks), and the effects were maintained for 2 to 4 weeks. Plasmapheresis lowered the titre of HTLV-I antibody in serum but not in cerebrospinal fluid, and change of HTLV-I antibody titres did not correlate with the effects of plasmapheresis. These results suggest that plasmapheresis is useful treatment, at least in producing a temporary improvement, in patients with HAM, and that some humoral factor(s), but not HTLV-I antibody, may be important in the pathogenesis of HAM.